Standardized ultrasound as a new method to induce platelet aggregation: Evaluation, influence of lipoproteins and of glycoprotein IIb/IIIa antagonist tirofiban

European Journal of Ultrasound

Volumn 14, Issue 2-3, 2001, Pages 157-166

  Otto, Carsten ^a   Baumann, Martin ^b   Schreiner, Thomas ^c   Bartsch, Guido ^b   Borberg, Helmut ^c   Schwandt, Peter ^a   Schmid Schönbein, Holger ^b  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^b RWTH AACHEN UNIVERSITY   (Germany)

^c Deutsches Hamapherese Zentrum   (Germany)

Author keywords

Hyperlipidemia; Platelet aggregation; Tirofiban; Ultrasound

Indexed keywords

COMPUTER SIMULATION; PHYSIOLOGY; PLASTICS; PROTEINS; ULTRASONIC DEVICES;

PLATELET AGGREGATION;

ULTRASONIC APPLICATIONS;

FIBRINOGEN; FIBRINOGEN RECEPTOR ANTAGONIST; LIPID; LIPOPROTEIN; TIROFIBAN;

ADULT; APHERESIS; ARTICLE; ATHEROSCLEROSIS; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN CELL; HYPERCHOLESTEROLEMIA; HYPERLIPIDEMIA; MALE; PRIORITY JOURNAL; TECHNIQUE; THROMBOCYTE AGGREGATION; ULTRASOUND;

BLOOD PLATELETS; CHOLESTEROL, LDL; HUMANS; MALE; PLATELET AGGREGATION; PLATELET AGGREGATION INHIBITORS; PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX; STATISTICS, NONPARAMETRIC; STIMULATION, CHEMICAL; TRIGLYCERIDES; TYROSINE; ULTRASONOGRAPHY;

EID: 0034751450     PISSN: 09298266     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0929-8266(01)00157-4     Document Type: Article

References (31)

1. Pharmacokinetics and pharmacodynamics of MK-383, a selective non-peptide platelet glycoprotein-IIb/IIIa receptor antagonist, in healthy men
2. Platelet changes after a saturated fat meal and their prevention by Dazmegrel, a thromboxane synthetase inhibitor
3. A platelet aggregometer with automatic data processing
4. Effects of selective LDL-apheresis and pravastatin therapy on platelet function in familial hypercholesterolemia
5. Alimentary lipemia enhances the membrane expression of platelet P-selectin without affecting other markers of platelet activation
6. Platelet function in hyperlipoproteinemia
7. Platelet aggregation induced in vitro by therapeutic ultrasound
8. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without the use of the preparative ultracentrifugation
9. Increased platelet aggregation during alimentary hyperlipemia in normal and hypertriglyceridemic subjects
10. Characterization of the unique mechanism mediating the shear-dependent binding of soluble von Willebrand factor to platelets
11. Acute postprandial lipaemia does not influence the in vivo activity of human platelets
12. The effect of a fat meal on platelet function in man
13. Remnant-like lipoproteins stimulate whole blood platelet aggregation in vitro
14. Platelet aggregation induced by ultrasound under specialised conditions in vitro
15. High shear stress can initiate both platelet aggregation and shedding of procoagulant containing microparticles
16. Involvement of large plasma von Willebrand Factor (vWF) multimers and unusually large vWF forms derived from endothelial cells in shear stress-induced platelet aggregation
17. The in vitro effects of chylomicron remnant and very low density lipoprotein remnant on platelet aggregation in blood obtained from healthy persons
18. Postprandial hyperlipemia inhibits platelet aggregation without affecting prostanoid metabolism
19. + antiport in human platelets
20. + antiport in human platelets. A novel mechanism enhancing platelet activity in hypercholesterolemia
21. Effects of VLDL, chylomicrons, and chylomicron remnants on platelet aggregability
22. The pathogenesis of atherosclerosis: a perspective for the 1990s
23. 2+ induced by low frequency ultrasound in vitro
24. Aggregation of human blood platelets by remnant like lipoprotein particles of plasma chylomicrons and very low density lipoproteins
25. Ex-vivo and in-vivo platelet function in patients with severe hypercholesterolemia undergoing LDL-apheresis
26. A comprehensive evaluation of the heparin-manganese precipitation procedure for estimating high-density lipoprotein cholesterol
27. Release of β-thromboglobulin from human platelets by therapeutic intensities of ultrasound
28. Activation of platelets in platelet-rich plasma by rotablation is speed-dependent and can be inhibited by abciximab (c7E3 Fab; ReoPro)